In addition, plasma MMP-2 and MMP-9 were significantly reduced in breast cancer patients after surgery, so both MMP-2 and MMP-9 could be used as markers of breast cancer disease response to therapy (159). The gene discussed is MMP9; the disease is breast carcinoma.